ESR1 and invasive breast carcinoma: Raloxifene significantly reduced the incidence of invasive breast cancer (hazard ratio, 0.56; 95% CI, 0.38 to 0.83; p= 0.03), particularly ER-positive cases, with notable absolute risk reductions.